Jacobio Announces HK$34.17 Million Share Buy-back, Confirms RMB2.10 Billion Liquidity and Four-Year Cash Runway

Bulletin Express05-19

Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio) disclosed continued execution of its shareholder return strategy, repurchasing 747,800 shares under its general mandate up to 18 May 2026. The aggregate outlay reached HK$34.17 million, and the repurchased shares have been placed in treasury. Management reiterated that the programme underlines confidence in the company’s long-term fundamentals and will proceed subject to market conditions.

Recent inflows have bolstered Jacobio’s balance sheet. The group has collected a US$100.00 million upfront payment from its strategic collaboration with AstraZeneca and an RMB8.55 million royalty from Allist covering June–December 2025 sales. Including these receipts, cash and bank balances, capital-protected structured deposits and committed credit lines total approximately RMB2.10 billion, providing a cash runway of at least four years based on current spending plans.

The board stated that ample liquidity, a progressing oncology pipeline and collaborations with multinationals underpin the company’s view that its market valuation does not yet capture its intrinsic or commercial potential. Jacobio intends to keep monitoring market conditions and may deploy further share buy-backs under the existing mandate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130241231?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 06:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130241231","market":"us","top_or_hot":-1,"title":"Jacobio Announces HK$34.17 Million Share Buy-back, Confirms RMB2.10 Billion Liquidity and Four-Year Cash Runway","media":"Bulletin Express","content":"<p>Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio) disclosed continued execution of its shareholder return strategy, repurchasing 747,800 shares under its general mandate up to 18 May 2026. The aggregate outlay reached HK$34.17 million, and the repurchased shares have been placed in treasury. Management reiterated that the programme underlines confidence in the company’s long-term fundamentals and will proceed subject to market conditions.</p>\n<p>Recent inflows have bolstered Jacobio’s balance sheet. The group has collected a US$100.00 million upfront payment from its strategic collaboration with AstraZeneca and an RMB8.55 million royalty from Allist covering June–December 2025 sales. Including these receipts, cash and bank balances, capital-protected structured deposits and committed credit lines total approximately RMB2.10 billion, providing a cash runway of at least four years based on current spending plans.</p>\n<p>The board stated that ample liquidity, a progressing oncology pipeline and collaborations with multinationals underpin the company’s view that its market valuation does not yet capture its intrinsic or commercial potential. Jacobio intends to keep monitoring market conditions and may deploy further share buy-backs under the existing mandate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Announces HK$34.17 Million Share Buy-back, Confirms RMB2.10 Billion Liquidity and Four-Year Cash Runway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Announces HK$34.17 Million Share Buy-back, Confirms RMB2.10 Billion Liquidity and Four-Year Cash Runway\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-19 06:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio) disclosed continued execution of its shareholder return strategy, repurchasing 747,800 shares under its general mandate up to 18 May 2026. The aggregate outlay reached HK$34.17 million, and the repurchased shares have been placed in treasury. Management reiterated that the programme underlines confidence in the company’s long-term fundamentals and will proceed subject to market conditions.</p>\n<p>Recent inflows have bolstered Jacobio’s balance sheet. The group has collected a US$100.00 million upfront payment from its strategic collaboration with AstraZeneca and an RMB8.55 million royalty from Allist covering June–December 2025 sales. Including these receipts, cash and bank balances, capital-protected structured deposits and committed credit lines total approximately RMB2.10 billion, providing a cash runway of at least four years based on current spending plans.</p>\n<p>The board stated that ample liquidity, a progressing oncology pipeline and collaborations with multinationals underpin the company’s view that its market valuation does not yet capture its intrinsic or commercial potential. Jacobio intends to keep monitoring market conditions and may deploy further share buy-backs under the existing mandate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1130241231","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130241231","pubTimestamp":1779141873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio) disclosed continued execution of its shareholder return strategy, repurchasing 747,800 shares under its general mandate up to 18 May 2026. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"雅可比奥宣布3417万港元回购股份，确认21.0亿元人民币流动性和四年现金跑道","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio) disclosed continued execution of its shareholder return strategy, repurchasing 747,800 shares under its general mandate up to 18 May 2026. The aggregate outlay reached HK$34.17 million, and the repurchased shares have been placed in treasury. Management reiterated that the programme underlines confidence in the company’s long-term fundamentals and will proceed subject to market conditions.\nRecent inflows have bolstered Jacobio’s balance sheet. The group has collected a US$100.00 million upfront payment from its strategic collaboration with AstraZeneca and an RMB8.55 million royalty from Allist covering June–December 2025 sales. Including these receipts, cash and bank balances, capital-protected structured deposits and committed credit lines total approximately RMB2.10 billion, providing a cash runway of at least four years based on current spending plans.\nThe board stated that ample liquidity, a progressing oncology pipeline and collaborations with multinationals underpin the company’s view that its market valuation does not yet capture its intrinsic or commercial potential. Jacobio intends to keep monitoring market conditions and may deploy further share buy-backs under the existing mandate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130241231","isCrawlerRequest":true}